{"DataElement":{"publicId":"7763727","version":"1","preferredName":"Follow-Up Performance Status Scale Timing Melanoma Type","preferredDefinition":"The type of melanoma performance status timing scale used during the follow-up period.","longName":"7763721v1.0:7752528v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7763721","version":"1","preferredName":"Follow-Up Performance Status Scale Timing","preferredDefinition":"Information regarding the follow-up period._A question about the performance status scale.","longName":"6848724v1.0:7643906v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"6848724","version":"1","preferredName":"Follow-Up Information","preferredDefinition":"Information regarding the follow-up period.","longName":"C156846","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follow-Up Information","conceptCode":"C156846","definition":"Information regarding the follow-up period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FEAD7AE-FE8D-57C6-E053-F662850A0798","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"ONEDATA","dateModified":"2019-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7643906","version":"1","preferredName":"Performance Status Scale: Timing","preferredDefinition":"A question about the performance status scale.","longName":"C158725","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Performance Status Scale: Timing","conceptCode":"C158725","definition":"A question about the performance status scale.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0F6CC03-3948-2708-E053-4EBD850A491B","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-04-27","modifiedBy":"ONEDATA","dateModified":"2021-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C9277A58-073F-7BC8-E053-4EBD850A1F8F","latestVersionIndicator":"Yes","beginDate":"2021-08-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-09","modifiedBy":"ONEDATA","dateModified":"2021-08-09","changeDescription":"8/9/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7752528","version":"1","preferredName":"Performance Status Scale Timing Melanoma Type","preferredDefinition":"A question about the performance status scale._A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain._Something distinguishable as an identifiable class based on common qualities.","longName":"7752528v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Induction","valueDescription":"Induction Therapy","ValueMeaning":{"publicId":"6859325","version":"1","preferredName":"Induction Therapy","longName":"6859325","preferredDefinition":"The first choice of treatment for a particular type of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Induction Therapy","conceptCode":"C158876","definition":"The first choice of treatment for a particular type of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"90A8573C-3838-34AF-E053-F662850A7E27","latestVersionIndicator":"Yes","beginDate":"2019-08-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-22","modifiedBy":"GDEEN","dateModified":"2023-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C84ECB02-5468-1BA0-E053-4EBD850AD338","beginDate":"2021-07-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","deletedIndicator":"No"},{"value":"Not Evaluated","valueDescription":"Source Data Not Available","ValueMeaning":{"publicId":"4842575","version":"1","preferredName":"Source Data Not Available","longName":"4842575","preferredDefinition":"Data from an original source is not present, accessible or ready for use or service.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Source Data Not Available","conceptCode":"C67329","definition":"Data from an original source is not present, accessible or ready for use or service.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"173BF844-9709-E098-E050-BB89AD431F3E","latestVersionIndicator":"Yes","beginDate":"2015-05-29","endDate":null,"createdBy":"LEEW","dateCreated":"2015-05-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C84ECB02-547D-1BA0-E053-4EBD850AD338","beginDate":"2021-04-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C84ECB02-5487-1BA0-E053-4EBD850AD338","beginDate":"2021-04-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Indeterminate or Unknown","ValueMeaning":{"publicId":"6841632","version":"1","preferredName":"Indeterminate or Unknown","longName":"6841632","preferredDefinition":"An indication that something is indeterminate or unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate or Unknown","conceptCode":"C157157","definition":"An indication that something is indeterminate or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C86-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C84ECB02-549B-1BA0-E053-4EBD850AD338","beginDate":"2021-04-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","deletedIndicator":"No"},{"value":"Consolidation","valueDescription":"Consolidation Therapy","ValueMeaning":{"publicId":"3828965","version":"1","preferredName":"Consolidation Therapy","longName":"3828965","preferredDefinition":"Treatment that is given after initial therapy to kill any remaining cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Consolidation Therapy","conceptCode":"C15679","definition":"Treatment that is given after initial therapy to kill any remaining cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2C14-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-29","modifiedBy":"GDEEN","dateModified":"2023-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C85739EC-337B-2DE4-E053-4EBD850A2078","beginDate":"2021-07-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-30","modifiedBy":"ONEDATA","dateModified":"2021-07-30","deletedIndicator":"No"},{"value":"Maintenance","valueDescription":"Maintenance Therapy","ValueMeaning":{"publicId":"3828964","version":"1","preferredName":"Maintenance Therapy","longName":"3828964","preferredDefinition":"Continuation of treatment for an extended period of time to prevent relapse.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maintenance Therapy","conceptCode":"C15688","definition":"Continuation of treatment for an extended period of time to prevent relapse.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2BF1-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-29","modifiedBy":"GDEEN","dateModified":"2023-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C85739EC-3385-2DE4-E053-4EBD850A2078","beginDate":"2021-07-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-30","modifiedBy":"ONEDATA","dateModified":"2021-07-30","deletedIndicator":"No"},{"value":"Salvage","valueDescription":"Salvage therapy (therapy after disease progression)","ValueMeaning":{"publicId":"3443018","version":"1","preferredName":"Salvage therapy (therapy after disease progression)","longName":"3443018","preferredDefinition":"Treatment that is given after the cancer has not responded to other treatments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Salvage Therapy","conceptCode":"C15359","definition":"Performing a salvage procedure is the last resort. The clinical situation involves either ongoing life support measures, life support measures for more than 60 seconds during the prior 10 minutes, or unanticipated institution of extracorporeal circulatory support. (ACC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE94F82C-D844-3AC1-E040-BB89AD435B3F","latestVersionIndicator":"Yes","beginDate":"2012-04-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C85739EC-338F-2DE4-E053-4EBD850A2078","beginDate":"2021-07-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-30","modifiedBy":"ONEDATA","dateModified":"2021-07-30","deletedIndicator":"No"},{"value":"Re-Induction","valueDescription":"Reinduction Therapy","ValueMeaning":{"publicId":"7240272","version":"1","preferredName":"Reinduction Therapy","longName":"7240272","preferredDefinition":"Treatment administered after a relapse of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reinduction Therapy","conceptCode":"C158877","definition":"Treatment administered after a relapse of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2B7048D-04A8-5762-E053-F662850A2535","latestVersionIndicator":"Yes","beginDate":"2020-04-07","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C85739EC-33A4-2DE4-E053-4EBD850A2078","beginDate":"2021-07-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-30","modifiedBy":"ONEDATA","dateModified":"2021-07-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7752527","version":"1","preferredName":"Performance Status Scale: Timing Melanoma Type","preferredDefinition":"A question about the performance status scale.:A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.:Something distinguishable as an identifiable class based on common qualities.","longName":"C158725:C3224:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Performance Status Scale: Timing","conceptCode":"C158725","definition":"A question about the performance status scale.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C84ECB02-5435-1BA0-E053-4EBD850AD338","latestVersionIndicator":"Yes","beginDate":"2021-07-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C84ECB02-5446-1BA0-E053-4EBD850AD338","latestVersionIndicator":"Yes","beginDate":"2021-07-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-29","modifiedBy":"KNABLEJ","dateModified":"2021-07-30","changeDescription":"7/29/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"10000348","version":"1","longName":"Melanoma","context":"OCCPR"},{"publicId":"7634325","version":"1","longName":"CM Follow Up","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Performance Status Scale: Tim","type":"Preferred Question Text","description":"Performance Status Scale: Timing","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C927BFE9-D708-4735-E053-4EBD850A47DF","latestVersionIndicator":"Yes","beginDate":"2021-08-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-09","modifiedBy":"KNABLEJ","dateModified":"2021-08-09","changeDescription":"8/9/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}